Royalty Pharma plc — Operating Income by Fiscal Year
8 fiscal years, as filed with the SEC; every row links its evidence fact.
Cite as: FACTANKER, https://factanker.com/entity/3f59737f-43a5-4b86-98dc-b8dbef5a314d/serie/operating-income
| Fiscal year | Operating Income | Period | Evidence |
|---|---|---|---|
| FY 2025 | $1.6B | 2025-01-01 – 2025-12-31 | evidence 0001802768-26-000003 |
| FY 2024 | $1.3B | 2024-01-01 – 2024-12-31 | evidence 0001802768-25-000010 |
| FY 2023 | $1.5B | 2023-01-01 – 2023-12-31 | evidence 0001802768-24-000012 |
| FY 2022 | $307.1M | 2022-01-01 – 2022-12-31 | evidence 0001802768-23-000007 |
| FY 2021 | $1.4B | 2021-01-01 – 2021-12-31 | evidence 0001802768-22-000011 |
| FY 2020 | $1.6B | 2020-01-01 – 2020-12-31 | evidence 0001802768-21-000006 |
| FY 2019 | $2.6B | 2019-01-01 – 2019-12-31 | evidence 0001802768-21-000006 |
| FY 2018 | $1.4B | 2018-01-01 – 2018-12-31 | evidence 0001802768-21-000006 |
Methodology & sources
One value per fiscal year (period > 300 days, latest period end per year); fiscal years ending Jun–Dec count toward the ending calendar year, Jan–May toward the prior year. Values as filed (XBRL concept per evidence fact). Source: SEC EDGAR (public domain).
One value per fiscal year (period > 300 days, latest period end per year); fiscal years ending Jun–Dec count toward the ending calendar year, Jan–May toward the prior year. Values as filed (XBRL concept per evidence fact). Source: SEC EDGAR (public domain).